← All Merck & Co, INC filings

Merck & Co, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
MRK
Merck & Co, INC
10-K: Merck Navigates Patent Cliffs, IRA Headwinds with Pipeline Growth
Merck reports modest 2025 sales growth driven by oncology and animal health, while facing significant patent expirations and IRA pricing pressures on key products, alongside strategic acquisitions and pipeline advancements.
NYSE
MRK
Merck & Co, INC
10-K: Merck & Co. Reports Strong 2024 Performance Driven by Oncology, Issues Guidance for 2025
Merck & Co.'s 2024 annual report reveals robust sales growth driven by its oncology portfolio, particularly Keytruda, while also outlining challenges and strategic initiatives for the future.
NYSE
MRK
Merck & Co, INC
10-K/A: Merck & Co. Amends Annual Report to Correct Shareholder Meeting Date
Merck & Co. has filed an amendment to its annual report to correct the date of the annual shareholder meeting from May 18, 2024 to May 28, 2024.
NYSE
MRK
Merck & Co, INC
10-K: Merck & Co. Outlines 2023 Performance, Strategic Priorities in Annual 10-K Filing
Merck & Co.'s 2023 10-K filing details a year of growth driven by oncology and vaccines, alongside strategic investments and pipeline advancements.